Showing results (1831-1840 of 6,238) with videos related to
Sort By:
Pageof 624
Nature Medicine|March 3, 2021
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasmaConstantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.Nature Medicine|February 23, 2021
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myelomaMatteo C Da Vià, Oliver Dietrich, Marietta Truger, et al.Nature Medicine|February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanomaE A Rozeman, E P Hoefsmit, I L M Reijers, et al.Nature Medicine|February 9, 2021
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited seraXuping Xie, Yang Liu, Jianying Liu, et al.Nature Medicine|February 9, 2021
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancersNisha B Nagarsheth, Scott M Norberg, Andrew L Sinkoe, et al.Nature Medicine|September 15, 2022
Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseasesGianluca Ianiro, Michal Punčochář, Nicolai Karcher, et al.Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.Nature Medicine|September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancerElena Elez, Javier Ros, Jose Fernández, et al.Nature Medicine|September 13, 2022
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaNicholas J Haradhvala, Mark B Leick, Katie Maurer, et al.Nature Medicine|September 13, 2022
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapyZinaida Good, Jay Y Spiegel, Bita Sahaf, et al.Pageof 624